The three Chinese domestic crown disease treatment drugs that have been approved have been included in the scope of medical insurance payment.
According to the press release issued on Wednesday (February 8), the official website of the China National Drug Administration, the person in chargeBoth belong to the scope of the tenth edition of the crown disease diagnosis and treatment plan. It has been temporarily incorporated into the scope of the province's basic medical insurance funds and will be paid until March 31 this year.
The previously approved Chinese medicine "three medicines and three parties" and Azf's fixed tablet have been officially included in the medical insurance catalog.Phaxlovid, Pfizer's imported crown disease, has not been included in the medical insurance list due to the failure of price negotiations and will only be temporarily paid until the end of March.
The person in charge of the pharmaceutical supervision bureau also said that the medical insurance bureau was required to perform the responsibilities of the competent department of drug prices in accordance with the law, and did a good job of the first quotation of the relevant drugs to accept and guide the relevant drugs.
China State Drug Administration attached conditions to approve Shanghai Wangshi Biomedical Technology Co., Ltd.'s crown disease therapy drug hydromodium bromide (product name: Minwei) andHainan Xianyou Pharmaceutical Co., Ltd.'s crown disease therapy drug Xiannutwe tablet/Litnavilian combination packaging (product name: Xian Nuoxin) is listed.
